Biogen’s Tecfidera Now The Most Prescribed Oral MS Therapy Globally

Stuart SchlossmanMS Drug Therapies

Cambridge,
Massachusetts based Biogen Inc. has reported its second quarter 2015 results,
posting a year-over-year seven percent revenue increase to $2.6 Billion in the
quarter. “Biogen remains focused on improving the lives of people living with
complex diseases,” says Chief Executive Officer George A. Scangos, Ph.D.
“Tecfidera, which is now the most prescribed oral MS […]

Read on »

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
 Keep CURRENT with MS Views and News – OPT-IN here
.========================================================
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews